Increased risk of hepatocellular carcinoma in patients infected with hepatitis C genotype 1bZEIN, N. N; POTERUCHA, J. J; GROSS, J. B et al.The American journal of gastroenterology. 1996, Vol 91, Num 12, pp 2560-2562, issn 0002-9270Article

High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitisIMAM, M. H; SINAKOS, E; PETZ, J et al.Alimentary pharmacology & therapeutics. 2011, Vol 34, Num 10, pp 1185-1192, issn 0269-2813, 8 p.Article

The clinical significance of simultaneous infection with Hepatitis G virus in patients with chronic Hepatitis CBRANDHAGEN, D. J; GROSS, J. B; WIESNER, R. H et al.The American journal of gastroenterology. 1999, Vol 94, Num 4, pp 1000-1005, issn 0002-9270Article

Treatment of chronic hepatitis C with interferon with or without ursodeoxycholic acid: A randomized prospective trialABDELMALEK, M. F; HARRISON, M. E; GROSS, J. B et al.Journal of clinical gastroenterology. 1998, Vol 26, Num 2, pp 130-134, issn 0192-0790Article